Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Effects of behavioral therapy or pharmacotherapy on brain glucose metabolism in subjects with obsessive-compulsive disorder as assessed by brain FDG PET.

Apostolova I, Block S, Buchert R, Osen B, Conradi M, Tabrizian S, Gensichen S, Schröder-Hartwig K, Fricke S, Rufer M, Weiss A, Hand I, Clausen M, Obrocki J.

Psychiatry Res. 2010 Nov 30;184(2):105-16. doi: 10.1016/j.pscychresns.2010.08.012. Epub 2010 Oct 14.

PMID:
20947317
2.

Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression.

Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, Ho MK, Huang SC, Wu HM, Baxter LR Jr.

Arch Gen Psychiatry. 2002 Mar;59(3):250-61.

PMID:
11879163
3.

The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study.

Hansen ES, Hasselbalch S, Law I, Bolwig TG.

Int J Neuropsychopharmacol. 2002 Mar;5(1):1-10.

PMID:
12057027
4.

Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression.

Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR Jr.

Am J Psychiatry. 2003 Mar;160(3):522-32.

PMID:
12611834
5.

Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder.

Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, Phelps ME, Baxter LR Jr.

Neuropsychopharmacology. 1999 Dec;21(6):683-93.

6.

Cerebral glucose metabolism in obsessive-compulsive hoarding.

Saxena S, Brody AL, Maidment KM, Smith EC, Zohrabi N, Katz E, Baker SK, Baxter LR Jr.

Am J Psychiatry. 2004 Jun;161(6):1038-48.

PMID:
15169692
7.

Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder.

Saxena S, Gorbis E, O'Neill J, Baker SK, Mandelkern MA, Maidment KM, Chang S, Salamon N, Brody AL, Schwartz JM, London ED.

Mol Psychiatry. 2009 Feb;14(2):197-205. doi: 10.1038/sj.mp.4002134. Epub 2008 Jan 8.

8.

Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder.

Schwartz JM, Stoessel PW, Baxter LR Jr, Martin KM, Phelps ME.

Arch Gen Psychiatry. 1996 Feb;53(2):109-13.

PMID:
8629886
9.

Effects of intensive cognitive-behavioral therapy on cingulate neurochemistry in obsessive-compulsive disorder.

O'Neill J, Gorbis E, Feusner JD, Yip JC, Chang S, Maidment KM, Levitt JG, Salamon N, Ringman JM, Saxena S.

J Psychiatr Res. 2013 Apr;47(4):494-504. doi: 10.1016/j.jpsychires.2012.11.010. Epub 2013 Jan 4.

10.

Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls.

Baxter LR Jr, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE.

Arch Gen Psychiatry. 1987 Mar;44(3):211-8. Erratum in: Arch Gen Psychiatry 1987 Sep;44(9):800.

PMID:
3493749
11.

Metabolic imaging of bilateral anterior capsulotomy in refractory obsessive compulsive disorder: an FDG PET study.

Zuo C, Ma Y, Sun B, Peng S, Zhang H, Eidelberg D, Guan Y.

J Cereb Blood Flow Metab. 2013 Jun;33(6):880-7. doi: 10.1038/jcbfm.2013.23. Epub 2013 Feb 27.

12.

Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.

Carey PD, Warwick J, Niehaus DJ, van der Linden G, van Heerden BB, Harvey BH, Seedat S, Stein DJ.

BMC Psychiatry. 2004 Oct 14;4:30.

13.

Long-term outcome in adults with obsessive-compulsive disorder.

Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, Landeros-Weisenberger A, Kelmendi B, Goodman WK, Leckman JF, Coric V, Pittenger C.

Depress Anxiety. 2013 Aug;30(8):716-22. doi: 10.1002/da.22103. Epub 2013 Mar 26.

14.

[18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment.

Perani D, Colombo C, Bressi S, Bonfanti A, Grassi F, Scarone S, Bellodi L, Smeraldi E, Fazio F.

Br J Psychiatry. 1995 Feb;166(2):244-50.

PMID:
7728370
15.

FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder.

Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, Baxter LR Jr.

Psychiatry Res. 1998 Nov 9;84(1):1-6.

PMID:
9870412
16.

Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy.

Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL, Rapoport SI, Rapoport JL, Grady CL.

Arch Gen Psychiatry. 1992 Sep;49(9):690-4.

PMID:
1514873
17.

Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently.

Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM, Huang SC, Wu HM, Au SC, Baxter LR Jr.

Biol Psychiatry. 2001 Aug 1;50(3):159-70.

PMID:
11513814
18.

Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial.

Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, Mayberg HS.

Am J Psychiatry. 2007 May;164(5):778-88.

PMID:
17475737
19.

L-3,4-Dihydroxy-6-[F-18]fluorophenylalanine positron emission tomography demonstrating dopaminergic system abnormality in the brains of obsessive-compulsive disorder patients.

Hsieh HJ, Lue KH, Tsai HC, Lee CC, Chen SY, Kao PF.

Psychiatry Clin Neurosci. 2014 Apr;68(4):292-8. doi: 10.1111/pcn.12139. Epub 2014 Jan 9.

20.

Bilateral orbitomedial leucotomy for obsessive-compulsive disorder: a single-case study using positron emission tomography.

Sachdev P, Trollor J, Walker A, Wen W, Fulham M, Smith JS, Matheson J.

Aust N Z J Psychiatry. 2001 Oct;35(5):684-90.

PMID:
11551286

Supplemental Content

Support Center